Art. -Nr.: HY-116767

BLT-1

(Synonyms: Block lipid transport-1)

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.93%
CAS. Nr.: 321673-30-7
Formel: C₁₂H₂₃N₃S
Molecular Weight:241.40

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BLT-1 Chemical Structure

CAS. Nr.: 321673-30-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
Chemical Information
Publications (13)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

In Vitro

BLT-1 has IC₅₀s of 60 and 110 nM for cellular DiI-HDL and [³H]CE-HDL uptake in ldlA[mSR-BI] cells^[1].
BLT-1 has an IC₅₀ of 0.96 μM for the HCV entry in Huh 7.5.1 cells^[4].
BLT-1 (50 μM; 3 hours) does not induce general defects in clathrin-dependent and -independent intracellular membrane trafficking in HeLa, BSC-1 cells^[1].
BLT-1 can inhibit SR-BI-dependent selective uptake of [³H]CE from [³H]CE-HDL by mSR-BI-t1-containing liposomes in cells (IC₅₀=0.057 μM) and liposomes (IC₅₀=0.098 μM) ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 321673-30-7
Appearance Solid
Molecular Weight 241.40
Formel C₁₂H₂₃N₃S
Color White to light yellow
SMILES

CCCCCCC1CCC/C1=N/NC(N)=S
Synonyms

Block lipid transport-1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (13)

All Cell Imaging/StainingIn Vivo Efficacy StudyIHCCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cancer Discov

Targeting UGCG overcomes resistance to lysosomal autophagy inhibition. [Abstract]

2023 Feb 6;13(2):454-473. PMID: 36331284

BLT-1 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2023 Feb 6;13(2):454-473. [Abstract]

Inhibition of the SR-B1 using the selective chemical inhibitor BLT-1 (5 µM) results in a modestly enhance DC661 cytotoxicity.
Cancer Res

Pancreatic Neuroendocrine Tumors Secrete Apolipoprotein E to Induce Tip Endothelial Cells That Remodel the Tumor-Stroma Ratio and Promote Cancer Progression. [Abstract]

2025 Aug 1;85(15):2805-2819. PMID: 40623046
Nat Commun

A hierarchical theranostic nanoagent for multimodal imaging and targeted foam cell intervention in atherosclerosis. [Abstract]

2026 Mar 11;17(1):3794. PMID: 41807467
Adv Sci (Weinh)

SR-B1-Mediated Transplacental Transfer of Hydrophobic Toxicants Disrupts Fetal Development During Barriergenesis. [Abstract]

2026 Apr;13(23):e15742. PMID: 41736660
Cardiovasc Res

Loss of GPR146 decreases plasma levels of HDL cholesterol via post-translational upregulation of SR-B1 protein levels. [Abstract]

2025 Nov 21:cvaf254. PMID: 41271608
Mol Ther

α-Tocopherol ameliorates allergic airway inflammation by regulating ILC2 ferroptosis in an LKB1-dependent manner. [Abstract]

2025 Dec 3;33(12):6518-6536. PMID: 40898617

BLT-1 purchased from MedChemExpress. Usage Cited in: Mol Ther. 2025 Dec 3;33(12):6518-6536. [Abstract]

BLT-1 (100 nM). Confocal laser scanning microscopy and quantification also revealed an increased proportion of γH2AX foci in PDCs after 48 h treatment. Scale bar, 10 μm.

BLT-1 purchased from MedChemExpress. Usage Cited in: Mol Ther. 2025 Dec 3;33(12):6518-6536. [Abstract]

Both TMZ treatment alone and BLT-1 (100 nM) + TMZ cotreatment effectively reduced the growth of PDOs after 72 h treatment. Confocal images β-catenin in organoid co-treated with TMZ and BLT-1 and quantification of the mean intensity. Scale bar, 50 μm.

BLT-1 purchased from MedChemExpress. Usage Cited in: Mol Ther. 2025 Dec 3;33(12):6518-6536. [Abstract]

Effect of TMZ treatment alone and BLT-1 (50 mg/kg/day, oral gavage for 3 weeks) + TMZ in PDX. Tumor weight, Tumor growth curves, and Representative graphs of tumors.

BLT-1 purchased from MedChemExpress. Usage Cited in: Mol Ther. 2025 Dec 3;33(12):6518-6536. [Abstract]

IHC staining of PDX showed that the higher expression of β-catenin, and BRCA1/2 induced by TMZ was reversed by BLT-1 (50 mg/kg/day, oral gavage for 3 weeks) + TMZ. Scale bar, 50 μm.
Cell Death Dis

Tumor-derived apolipoprotein E confers resistance to temozolomide in pancreatic neuroendocrine tumors. [Abstract]

2025 Dec 13. PMID: 41390817
Food Res Int

Hydroxypropyl-β-cyclodextrin as a co-delivery vehicle for synergistically enhancing fucoxanthin oral bioavailability through dual regulation of SR-B1 and ABCB1 transporters. [Abstract]

2026 Mar 31:228:118352. PMID: 41703824
Cell Rep

Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. [Abstract]

2025 Jun 6;44(6):115792. PMID: 40483692
Nutrients

2026 Jan;18(9):1389.
FEBS J

TNF-α/ENO1 signaling facilitates testicular phagocytosis by directly activating Elmo1 gene expression in mouse Sertoli cells. [Abstract]

2022 May;289(10):2809-2827. PMID: 34919331
iScience

Dendritic cells overcome Cre/Lox induced gene deficiency by siphoning cytosolic material from surrounding cells. [Abstract]

2024 Feb 6;27(3):109119. PMID: 38384841
bioRxiv

2026 Jun 1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 41.67 mg/mL (172.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1425 mL

20.7125 mL

41.4250 mL

5 mM

0.8285 mL

4.1425 mL

8.2850 mL

10 mM

0.4143 mL

2.0713 mL

4.1425 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (8.62 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nieland TJ, et al. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptorSR-BI. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15422-7. [Content Brief]

[2]. Nieland TJ, et al. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry. 2008 Jan 8;47(1):460-72. [Content Brief]

[3]. Raldúa D, et al. BLT-1, a specific inhibitor of the HDL receptor SR-BI, induces a copper-dependent phenotype during zebrafish development. Toxicol Lett. 2007 Dec 10;175(1-3):1-7. Epub 2007 Aug 22. [Content Brief]

[4]. Hirofumi Ohashi, et al. Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments. Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.1425 mL	20.7125 mL	41.4250 mL	103.5626 mL
	5 mM	0.8285 mL	4.1425 mL	8.2850 mL	20.7125 mL
	10 mM	0.4143 mL	2.0713 mL	4.1425 mL	10.3563 mL
	15 mM	0.2762 mL	1.3808 mL	2.7617 mL	6.9042 mL
	20 mM	0.2071 mL	1.0356 mL	2.0713 mL	5.1781 mL
	25 mM	0.1657 mL	0.8285 mL	1.6570 mL	4.1425 mL
	30 mM	0.1381 mL	0.6904 mL	1.3808 mL	3.4521 mL
	40 mM	0.1036 mL	0.5178 mL	1.0356 mL	2.5891 mL
	50 mM	0.0829 mL	0.4143 mL	0.8285 mL	2.0713 mL
	60 mM	0.0690 mL	0.3452 mL	0.6904 mL	1.7260 mL
	80 mM	0.0518 mL	0.2589 mL	0.5178 mL	1.2945 mL
	100 mM	0.0414 mL	0.2071 mL	0.4143 mL	1.0356 mL

BLT-1

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BLT-1

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Antiviral Compound Library

Anti-Hepatitis C Virus Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BLT-1

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BLT-1

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Antiviral Compound Library

Anti-Hepatitis C Virus Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BLT-1

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BLT-1 Related Classifications

HY-116767 Related Classifications